MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25024-25033

  Tong, Yong Qing ^a   Liu, Bei ^b   Zheng, Hong Yun ^a   Gu, Jian ^a   Liu, Hang ^a   Li, Feng ^a   Tan, Bi Hua ^c   Hartman, Melanie ^c   Song, Chunhua ^c   Li, Yan ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

CTNNBIP1; Glioma; miR 215; Prognosis; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; BETA CATENIN; BINDING PROTEIN; FIBRONECTIN; MICRORNA; MICRORNA 215; PROTEIN CTNNBIP1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WNT PROTEIN; CTNNBIP1 PROTEIN, HUMAN; MIRN215 MICRORNA, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENDER; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA; WESTERN BLOTTING; WNT SIGNALING PATHWAY; YOUNG ADULT;

ADULT; AGED; BETA CATENIN; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BRAIN NEOPLASMS; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84944462949     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4622     Document Type: Article

References (36)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012; 379:1984-1996.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007; 114:97-109.
3. Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surgical neurology international. 2014; 5:64.
4. Auffinger B, Ahmed AU, Lesniak MS. Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Frontiers in oncology. 2013; 3:32.
5. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, Consortium NC. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:2443-2449.
6. Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010; 14:236-240.
7. Li Y, Li Z, Zhou S, Wen J, Geng B, Yang J, Cui Q. Genome-wide analysis of human microRNA stability. BioMed research international. 2013; 2013:368975.
8. Lee HK, Bier A, Cazacu S, Finniss S, Xiang C, Twito H, Poisson LM, Mikkelsen T, Slavin S, Jacoby E, Yalon M, Toren A, Rempel SA, Brodie C. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PloS one. 2013; 8:e54652.
9. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, deCarvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T, Brodie C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4:665-676.
10. Niu CS, Yang Y, Cheng CD. MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. International journal of oncology. 2013; 42:1533-1540.
11. Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 2015; 17:34-40.
12. Mu J, Pang Q, Guo YH, Chen JG, Zeng W, Huang YJ, Zhang J, Feng B. Functional implications of microRNA-215 in TGF-beta1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PloS one. 2013; 8:e58622.
13. Kaminska B, Kocyk M, Kijewska M. TGF beta signaling and its role in glioma pathogenesis. Advances in experimental medicine and biology. 2013; 986:171-187.
14. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. Rna. 2009; 15:1443-1461.
15. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nature reviews Clinical oncology. 2011; 8:75-84.
16. Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Molecular neurobiology. 2013; 47:131-144.
17. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and biophysical research communications. 2005; 334:1351-1358.
18. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer research. 2005; 65:6029-6033.
19. Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, Olaru AV, Yang J, David S, Hamilton JP, Abraham JM, Harmon J, Duncan M, Montgomery EA, Meltzer SJ. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene. 2011; 30:1577-1585.
20. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer research. 2010; 70:2339-2349.
21. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. The Lancet Oncology. 2010; 11:136-146.
22. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical science. 2006; 110:525-541.
23. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. Journal of clinical pathology. 2006; 59:445-453.
24. Liang H, Li Y, Luo RY, Shen FJ. MicroRNA-215 is a potential prognostic marker for cervical cancer. J Huazhong Univ Sci Technolog Med Sci. 2014; 34:207-212.
25. Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015; 17:34-40.
26. Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly expressed microRNAs in prostate cancer. International journal of urology: official journal of the Japanese Urological Association. 2015.
27. Adjakly M, Ngollo M, Dagdemir A, Judes G, Pajon A, Karsli-Ceppioglu S, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D. Prostate cancer: The main risk and protective factors -Epigenetic modifications. Ann Endocrinol (Paris). 2015; 76:25-41.
28. Yu JJ, Xia SJ. Novel role of microRNAs in prostate cancer. Chinese medical journal. 2013; 126:2960-2964.
29. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA, Chau BN. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer research. 2008; 68:10105-10112.
30. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer research. 2008; 68:10094-10104.
31. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr., Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer cell. 2010; 18:367-381.
32. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, Wang J. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2014; 33:5332-5340.
33. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA, Yousef GM. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 2013; 34:2231-2239.
34. Hu F, Meng X, Tong Q, Liang L, Xiang R, Zhu T, Yang S. BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. Biochimica et biophysica acta. 2013; 1832:2379-2390.
35. Ye M, Zhang J, Zhang J, Miao Q, Yao L, Zhang J. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer letters. 2015; 357:196-205.
36. Yang WB, Li CY. Correlations of MUC15 overexpression with clinicopathological features and prognosis of glioma. J Huazhong Univ Sci Technolog Med Sci. 2014; 34:254-259.